Inozyme Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Inozyme Pharma generated cash of -$70,675,000, which is less than the previous year. Cash used in financing activities reached the amount of $125,969,000 last year. Net change in cash is therefore $1,630,000.
Cash Flow
| 2018 | -9.43M | 9.00M | 31.94M |
|---|---|---|---|
| 2019 | -18.81M | -8.39M | 22.97M |
| 2020 | -35.97M | -117.17M | 149.81M |
| 2021 | -48.15M | 42.79M | 609K |
| 2022 | -57.76M | -5.40M | 72.78M |
| 2023 | -70.67M | -53.64M | 125.96M |
INZY Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 33.26M | 23.67M | 28.39M | 31.73M | 35.96M | 4.45M |
Operating activities | ||||||
Net income | -71.16M | -67.06M | -56.62M | -56.42M | -19.72M | -6.96M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 833K | 744K | 674K | 217K | 83K | 26K |
Stock-based compensation expense | 7.03M | 7.67M | 7.16M | 2.30M | 301K | 0 |
| Deferred income tax benefit | 7.03M | 7.67M | 7.16M | 2.30M | 301K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.37M | 150K | -675K | 2.09M | -83K | 802K |
Cash generated by operating activities | -70.67M | -57.76M | -48.15M | -35.97M | -18.81M | -9.43M |
Investing activities | ||||||
Purchases Of Investments | -269.33M | -151.99M | -121.96M | -177.92M | -24.66M | -13.56M |
Investments In Property Plant And Equipment | -298K | -410K | -397K | -568K | -139K | -259K |
Acquisitions Net | 0 | 4.99K | -43.19K | 116.61K | 8.25K | 0 |
Cash generated by investing activities | -53.64M | -5.40M | 42.79M | -117.17M | -8.39M | 9.00M |
Financing activities | ||||||
Common Stock Issued | 85.64M | 56.13M | 609K | 115.97M | 22.97M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 40M | 4.05M | 0 | 0 | 0 | 0 |
Cash used in financing activities | 125.96M | 72.78M | 609K | 149.81M | 22.97M | 31.94M |
Net Change In Cash | 1.63M | 9.59M | -4.72M | -3.34M | -4.23M | 31.51M |
Cash at end of period | 34.89M | 33.26M | 23.67M | 28.39M | 31.73M | 35.96M |
| Data source | Data source | Data source | Data source |